News Releases
View printer-friendly version < < backNEW BRUNSWICK, N.J., July 20, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.
Net earnings and diluted earnings per share for the second quarter of 2010 were $3.4 billion and $1.23, respectively. Second-quarter 2010 net earnings included an after-tax gain of $67 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.21, representing increases of 5.4% and 5.2%, respectively, as compared to the same period in 2009.*
The Company updated its earnings guidance for full-year 2010 to $4.65 - $4.75 per share, which excludes the impact of special items. The Company's guidance now reflects the impact of the voluntary recalls announced earlier this year of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as unfavorable changes in foreign currency exchange rates.
"Our second-quarter results include strong growth in a number of our recently launched products which contributed to solid earnings," said William C. Weldon, Chairman and Chief Executive Officer. "Remedial actions to address the product quality issues at McNeil Consumer Healthcare are ongoing and of high importance. At the same time, we continue to make significant investments in acquisitions, strategic partnerships and in advancing our pipeline, positioning us well for future growth."
Worldwide Consumer sales of $3.6 billion for the second quarter represented a decrease of 5.4% versus the prior year consisting of an operational decline of 6.5% and a positive impact from currency of 1.1%. Domestic sales decreased 14.3%; international sales increased 1.8%, which reflected an operational decline of 0.2% and a positive currency impact of 2.0%.
Positive contributors to operational results were NEUTROGENA(R), international sales of Baby Care products and JOHNSON'S(R) adult skin products. These operational sales increases were more than offset by the impact of the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the economic situation in Venezuela.
Worldwide Pharmaceutical sales of $5.6 billion for the second quarter represented an increase of 1.0% versus the prior year with operational growth of 1.0% with no impact from currency. Domestic sales decreased 2.0%; international sales increased 5.0%, which reflected an operational increase of 4.9% and a positive currency impact of 0.1%.
Sales growth includes the strong performance of newly launched products including STELARA(TM) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI(TM) (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.
Several other products had strong operational growth including PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; international sales of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication; and INTELENCE(R)(etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV.
Sales results of TOPAMAX(R) (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL(R) (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.
During the quarter, the Company acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.
Additionally the Company signed an exclusive agreement with Diamyd Medical AB to develop and commercialize the GAD65 antigen-based diabetes therapy.
Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented an increase of 4.1% versus the prior year consisting of an operational increase of 3.5% and a positive currency impact of 0.6%. Domestic sales increased 3.2%; international sales increased 5.0%, which reflected an operational increase of 3.9% and a positive currency impact of 1.1%.
Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.
During the quarter, the Company received clearance from the United States Food and Drug Administration to market narafilcon B, the first and only silicone hydrogel daily disposable contact lens in the United States, which will be marketed under the name 1-DAY ACUVUE(R) TruEye(TM) Brand Contact Lenses.
In July, the Company entered into a definitive agreement to acquire Micrus Endovascular, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke. Also in July, Ethicon Endo-Surgery completed the divestiture of its Breast Care business to Devicor Medical Products, Inc.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Net earnings and diluted earnings per share excluding special items, such as the net impact of litigation gains, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure can be found in the Investor Relations section of the Company's website at www.jnj.com.
NOTE TO INVESTORS
Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited;
Dollars in
Millions) SECOND QUARTER
----------- --------------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to
customers by
segment of
business
Consumer
U.S. $1,463 1,708 (14.3)% (14.3) -
International 2,184 2,146 1.8 (0.2) 2.0
------------- ----- ----- --- ---- ---
3,647 3,854 (5.4) (6.5) 1.1
===== ===== ==== ==== ===
Pharmaceutical
U.S. 3,110 3,172 (2.0) (2.0) -
International 2,443 2,326 5.0 4.9 0.1
------------- ----- ----- --- --- ---
5,553 5,498 1.0 1.0 0.0
===== ===== === === ===
Med Devices &
Diagnostics
U.S. 2,865 2,776 3.2 3.2 -
International 3,265 3,111 5.0 3.9 1.1
------------- ----- ----- --- --- ---
6,130 5,887 4.1 3.5 0.6
===== ===== === === ===
U.S. 7,438 7,656 (2.8) (2.8) -
International 7,892 7,583 4.1 3.0 1.1
------------- ----- ----- --- --- ---
Worldwide $15,330 15,239 0.6% 0.1 0.5
========= ======= ====== === === ===
(Unaudited;
Dollars in
Millions) SIX MONTHS
----------- ----------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers
by
segment of
business
Consumer
U.S. $3,023 3,434 (12.0)% (12.0) -
International 4,390 4,131 6.3 0.6 5.7
------------- ----- ----- --- --- ---
7,413 7,565 (2.0) (5.1) 3.1
===== ===== ==== ==== ===
Pharmaceutical
U.S. 6,316 6,846 (7.7) (7.7) -
International 4,875 4,432 10.0 5.7 4.3
------------- ----- ----- ---- --- ---
11,191 11,278 (0.8) (2.5) 1.7
====== ====== ==== ==== ===
Med Devices &
Diagnostics
U.S. 5,751 5,428 6.0 6.0 -
International 6,606 5,994 10.2 5.6 4.6
------------- ----- ----- ---- --- ---
12,357 11,422 8.2 5.8 2.4
====== ====== === === ===
U.S. 15,090 15,708 (3.9) (3.9) -
International 15,871 14,557 9.0 4.2 4.8
------------- ------ ------ --- --- ---
Worldwide $30,961 30,265 2.3% 0.0 2.3
========= ======= ====== === === ===
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in
Millions) SECOND QUARTER
---------------------- --------------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $7,438 7,656 (2.8)% (2.8) -
---- ------ ----- ----- ---- ---
Europe 3,832 3,972 (3.5) 1.3 (4.8)
Western Hemisphere
excluding U.S. 1,375 1,215 13.2 2.6 10.6
Asia-Pacific, Africa 2,685 2,396 12.1 6.1 6.0
International 7,892 7,583 4.1 3.0 1.1
------------- ----- ----- --- --- ---
Worldwide $15,330 15,239 0.6% 0.1 0.5
========= ======= ====== === === ===
(Unaudited; Dollars in
Millions) SIX MONTHS
---------------------- ----------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers by
geographic area
U.S. $15,090 15,708 (3.9)% (3.9) -
---- ------- ------ ----- ---- ---
Europe 7,934 7,643 3.8 2.9 0.9
Western Hemisphere
excluding U.S. 2,655 2,277 16.6 3.1 13.5
Asia-Pacific, Africa 5,282 4,637 13.9 6.9 7.0
International 15,871 14,557 9.0 4.2 4.8
------------- ------ ------ --- --- ---
Worldwide $30,961 30,265 2.3% 0.0 2.3
========= ======= ====== === === ===
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions
Except Per Share Figures) SECOND QUARTER
-------------------------- --------------
2010 2009
---------------- ---------------- Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
---------------------------------------------------------------------
Sales to customers $15,330 100.0 $15,239 100.0 0.6
------------------ ------- ----- ------- ----- ---
Cost of products sold 4,630 30.2 4,450 29.2 4.0
Selling, marketing and
administrative expenses 4,756 31.0 4,797 31.5 (0.9)
Research expense 1,648 10.8 1,638 10.7 0.6
Interest (income)expense,
net 58 0.4 85 0.6
Other (income)expense,
net 18 0.1 6 -
---------------------- --- --- --- ---
Earnings before provision
for taxes on income 4,220 27.5 4,263 28.0 (1.0)
Provision for taxes on
income 771 5.0 1,055 6.9 (26.9)
--- --- -----
Net earnings $3,449 22.5 $3,208 21.1 7.5
============ ====== ==== ====== ==== ===
Net earnings per share
(Diluted) $1.23 $1.15 7.0
Average shares
outstanding (Diluted) 2,796.0 2,782.0
Effective tax rate 18.3% 24.7%
Adjusted earnings before
provision for taxes and
net earnings
Earnings before
provision for
taxes on income $4,377 (1) 28.6 $4,263 28.0 2.7
Net earnings $3,382 (1) 22.1 $3,208 21.1 5.4
Net earnings per
share (Diluted) $1.21 (1) $1.15 5.2
Effective tax
rate 22.7% 24.7%
------------- ---- ----
(1) The difference between as reported and as adjusted earnings is
the exclusion of second quarter net litigation. The impact of
second quarter net litigation is $157 million expense on earnings
before provision for taxes on income, $67 million income on net
earnings and $0.02 per share on net earnings per share (diluted).
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) SIX MONTHS
------------------- ----------
2010 2009
---------------- ---------------- Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
---------------------------------------------------------------------
Sales to customers $30,961 100.0 $30,265 100.0 2.3
------------------ ------- ----- ------- ----- ---
Cost of products sold 9,158 29.6 8,701 28.7 5.3
Selling, marketing and
administrative
expenses 9,535 30.8 9,405 31.1 1.4
Research expense 3,205 10.4 3,156 10.4 1.6
Interest
(income)expense, net 139 0.4 166 0.6
Other (income)expense,
net (1,576) (5.1) (69) (0.2)
---------------------- ------ ---- --- ----
Earnings before
provision for taxes
on income 10,500 33.9 8,906 29.4 17.9
Provision for taxes on
income 2,525 8.1 2,191 7.2 15.2
--- --- ----
Net earnings $7,975 25.8 $6,715 22.2 18.8
============ ====== ==== ====== ==== ====
Net earnings per share
(Diluted) $2.85 $2.41 18.3
Average shares
outstanding
(Diluted) 2,796.1 2,785.5
Effective tax rate 24.0% 24.6%
Adjusted earnings before
provision for taxes and
net earnings
Earnings before
provision for taxes
on income $9,160 (1) 29.6 $8,906 29.4 2.9
Net earnings $6,998 (1) 22.6 $6,715 22.2 4.2
Net earnings per
share (Diluted) $2.50 (1) $2.41 3.7
Effective tax rate 23.6% 24.6%
------------------ ---- ----
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings
per share (diluted) is the exclusion of income from net litigation
of $1,340 million, $977 million and $0.35 per share, respectively.
REPORTED SALES vs. PRIOR PERIOD ($MM)
-------------------------------------
SECOND QUARTER
--------------
% Change
--------
Operational
2010 2009 Reported (1) Currency
---- ---- -------- ------------ --------
CONSUMER SEGMENT (2)
--------------------
SKIN CARE
---------
US 422 411 2.7% 2.7% -
Intl 421 422 -0.2% -0.5% 0.3%
WW 843 833 1.2% 1.1% 0.1%
BABY CARE
---------
US 99 104 -4.8% -4.8% -
Intl 438 404 8.4% 4.9% 3.5%
WW 537 508 5.7% 2.9% 2.8%
ORAL CARE
---------
US 148 174 -14.9% -14.9% -
Intl 224 212 5.7% 1.8% 3.9%
WW 372 386 -3.6% -5.8% 2.2%
OTC/NUTRITIONALS
----------------
US 492 679 -27.5% -27.5% -
Intl 649 631 2.9% 1.9% 1.0%
WW 1,141 1,310 -12.9% -13.4% 0.5%
WOMEN'S HEALTH
--------------
US 137 152 -9.9% -9.9% -
Intl 329 329 0.0% -2.1% 2.1%
WW 466 481 -3.1% -4.5% 1.4%
WOUND CARE / OTHER
------------------
US 165 188 -12.2% -12.2% -
Intl 123 148 -16.9% -20.3% 3.4%
WW 288 336 -14.3% -15.8% 1.5%
TOTAL CONSUMER
--------------
US 1,463 1,708 -14.3% -14.3% -
Intl 2,184 2,146 1.8% -0.2% 2.0%
WW 3,647 3,854 -5.4% -6.5% 1.1%
----- ----- ---- ---- ---
* See footnotes below
PHARMACEUTICAL SEGMENT
(2) (6)
----------------------
ACIPHEX/PARIET
--------------
US 121 128 -5.5% -5.5% -
Intl 133 132 0.8% 2.1% -1.3%
WW 254 260 -2.3% -1.6% -0.7%
CONCERTA
--------
US 223 233 -4.3% -4.3% -
Intl 100 84 19.0% 16.3% 2.7%
WW 323 317 1.9% 1.2% 0.7%
DURAGESIC/FENTANYL
TRANSDERMAL
------------------
US 37 50 -26.0% -26.0% -
Intl 147 168 -12.5% -12.6% 0.1%
WW 184 218 -15.6% -15.7% 0.1%
LEVAQUIN/FLOXIN
---------------
US 289 343 -15.7% -15.7% -
Intl 11 19 -42.1% -44.8% 2.7%
WW 300 362 -17.1% -17.2% 0.1%
PREZISTA
--------
US 99 65 52.3% 52.3% -
Intl 105 75 40.0% 42.1% -2.1%
WW 204 140 45.7% 46.8% -1.1%
PROCRIT/EPREX
-------------
US 306 330 -7.3% -7.3% -
Intl 220 247 -10.9% -9.3% -1.6%
WW 526 577 -8.8% -8.1% -0.7%
REMICADE
--------
US 783 771 1.6% 1.6% -
US Exports (3) 341 327 4.3% 4.3% -
Intl 6 4 50.0% 50.0% -
WW 1,130 1,102 2.5% 2.5% -
RISPERDAL/RISPERIDONE
---------------------
US (17) 70 -124.3% -124.3% -
Intl 134 169 -20.7% -22.1% 1.4%
WW 117 239 -51.0% -52.0% 1.0%
RISPERDAL CONSTA
----------------
US 115 131 -12.2% -12.2% -
Intl 240 217 10.6% 12.8% -2.2%
WW 355 348 2.0% 3.4% -1.4%
TOPAMAX
-------
US 59 75 -21.3% -21.3% -
Intl 83 107 -22.4% -21.4% -1.0%
WW 142 182 -22.0% -21.4% -0.6%
VELCADE
-------
US - - - - -
Intl 286 229 24.9% 25.1% -0.2%
WW 286 229 24.9% 25.1% -0.2%
OTHER
-----
US 754 649 16.2% 16.2% -
Intl 978 875 11.8% 10.3% 1.5%
WW 1,732 1,524 13.6% 12.8% 0.8%
TOTAL PHARMACEUTICAL
--------------------
US 3,110 3,172 -2.0% -2.0% -
Intl 2,443 2,326 5.0% 4.9% 0.1%
WW 5,553 5,498 1.0% 1.0% 0.0%
----- ----- --- --- ---
MAJOR NEW PHARM
PRODUCTS (4)
---------------
INVEGA
------
US 68 67 1.5% 1.5% -
Intl 34 32 6.3% 8.3% -2.0%
WW 102 99 3.0% 3.6% -0.6%
--- --- --- --- ----
* See footnotes below
MEDICAL DEVICES AND
DIAGNOSTICS (2)
-------------------
CORDIS (5)
----------
US 265 252 5.2% 5.2% -
Intl 390 422 -7.6% -8.6% 1.0%
WW 655 674 -2.8% -3.4% 0.6%
DEPUY
-----
US 776 762 1.8% 1.8% -
Intl 599 561 6.8% 6.0% 0.8%
WW 1,375 1,323 3.9% 3.5% 0.4%
DIABETES CARE
-------------
US 313 306 2.3% 2.3% -
Intl 303 304 -0.3% 1.1% -1.4%
WW 616 610 1.0% 1.7% -0.7%
ETHICON
-------
US 509 452 12.6% 12.6% -
Intl 623 589 5.8% 5.0% 0.8%
WW 1,132 1,041 8.7% 8.2% 0.5%
ETHICON ENDO-SURGERY
--------------------
US 507 489 3.7% 3.7% -
Intl 689 626 10.1% 8.8% 1.3%
WW 1,196 1,115 7.3% 6.6% 0.7%
ORTHO-CLINICAL
DIAGNOSTICS
--------------
US 264 284 -7.0% -7.0% -
Intl 230 210 9.5% 8.4% 1.1%
WW 494 494 0.0% -0.5% 0.5%
VISION CARE
-----------
US 232 231 0.4% 0.4% -
Intl 430 399 7.8% 3.9% 3.9%
WW 662 630 5.1% 2.6% 2.5%
TOTAL MEDICAL DEVICES
AND DIAGNOSTICS
---------------------
US 2,865 2,776 3.2% 3.2% -
Intl 3,265 3,111 5.0% 3.9% 1.1%
WW 6,130 5,887 4.1% 3.5% 0.6%
----- ----- --- --- ---
SIX MONTHS
----------
% Change
--------
Operational
2010 2009 Reported (1) Currency
---- ---- -------- ------------ --------
CONSUMER SEGMENT (2)
--------------------
SKIN CARE
---------
US 874 834 4.8% 4.8% -
Intl 889 841 5.7% 0.9% 4.8%
WW 1,763 1,675 5.3% 2.9% 2.4%
BABY CARE
---------
US 202 206 -1.9% -1.9% -
Intl 864 791 9.2% 3.1% 6.1%
WW 1,066 997 6.9% 2.1% 4.8%
ORAL CARE
---------
US 322 362 -11.0% -11.0% -
Intl 431 389 10.8% 3.3% 7.5%
WW 753 751 0.3% -3.6% 3.9%
OTC/NUTRITIONALS
----------------
US 1,034 1,405 -26.4% -26.4% -
Intl 1,314 1,253 4.9% -0.5% 5.4%
WW 2,348 2,658 -11.7% -14.3% 2.6%
WOMEN'S HEALTH
--------------
US 283 301 -6.0% -6.0% -
Intl 652 603 8.1% 2.4% 5.7%
WW 935 904 3.4% -0.4% 3.8%
WOUND CARE / OTHER
------------------
US 308 326 -5.5% -5.5% -
Intl 240 254 -5.5% -11.4% 5.9%
WW 548 580 -5.5% -8.1% 2.6%
TOTAL CONSUMER
--------------
US 3,023 3,434 -12.0% -12.0% -
Intl 4,390 4,131 6.3% 0.6% 5.7%
WW 7,413 7,565 -2.0% -5.1% 3.1%
----- ----- ---- ---- ---
* See footnotes below
PHARMACEUTICAL
SEGMENT (2) (6)
-----------------
ACIPHEX/PARIET
--------------
US 240 266 -9.8% -9.8% -
Intl 274 257 6.6% 2.7% 3.9%
WW 514 523 -1.7% -3.6% 1.9%
CONCERTA
--------
US 454 502 -9.6% -9.6% -
Intl 198 159 24.5% 16.7% 7.8%
WW 652 661 -1.4% -3.3% 1.9%
DURAGESIC/FENTANYL
TRANSDERMAL
------------------
US 75 125 -40.0% -40.0% -
Intl 293 324 -9.6% -13.1% 3.5%
WW 368 449 -18.0% -20.5% 2.5%
LEVAQUIN/FLOXIN
---------------
US 652 751 -13.2% -13.2% -
Intl 19 36 -47.2% -50.2% 3.0%
WW 671 787 -14.7% -14.8% 0.1%
PREZISTA
--------
US 188 137 37.2% 37.2% -
Intl 203 125 62.4% 57.3% 5.1%
WW 391 262 49.2% 46.8% 2.4%
PROCRIT/EPREX
-------------
US 596 651 -8.4% -8.4% -
Intl 453 476 -4.8% -7.8% 3.0%
WW 1,049 1,127 -6.9% -8.2% 1.3%
REMICADE
--------
US 1,563 1,508 3.6% 3.6% -
US Exports (3) 741 613 20.9% 20.9% -
Intl 12 9 33.3% 33.2% 0.1%
WW 2,316 2,130 8.7% 8.7% -
RISPERDAL/RISPERIDONE
---------------------
US (12) 188 -106.4% -106.4% -
Intl 267 326 -18.1% -21.2% 3.1%
WW 255 514 -50.4% -52.4% 2.0%
RISPERDAL CONSTA
----------------
US 232 257 -9.7% -9.7% -
Intl 502 416 20.7% 16.9% 3.8%
WW 734 673 9.1% 6.8% 2.3%
TOPAMAX
-------
US 116 570 -79.6% -79.6% -
Intl 174 214 -18.7% -21.6% 2.9%
WW 290 784 -63.0% -63.8% 0.8%
VELCADE
-------
US - - 0.0% 0.0% -
Intl 547 421 29.9% 25.8% 4.1%
WW 547 421 29.9% 25.8% 4.1%
OTHER
-----
US 1,471 1,278 15.1% 15.1% -
Intl 1,933 1,669 15.8% 10.5% 5.3%
WW 3,404 2,947 15.5% 12.5% 3.0%
TOTAL PHARMACEUTICAL
--------------------
US 6,316 6,846 -7.7% -7.7% -
Intl 4,875 4,432 10.0% 5.7% 4.3%
WW 11,191 11,278 -0.8% -2.5% 1.7%
------ ------ ---- ---- ---
MAJOR NEW PHARM
PRODUCTS (4)
---------------
INVEGA
------
US 137 133 3.0% 3.0% -
Intl 73 57 28.1% 23.8% 4.3%
WW 210 190 10.5% 9.2% 1.3%
--- --- ---- --- ---
* See footnotes below
MEDICAL DEVICES AND
DIAGNOSTICS (2)
-------------------
CORDIS (5)
----------
US 516 498 3.6% 3.6% -
Intl 811 844 -3.9% -7.4% 3.5%
WW 1,327 1,342 -1.1% -3.3% 2.2%
DEPUY
-----
US 1,590 1,528 4.1% 4.1% -
Intl 1,239 1,087 14.0% 8.5% 5.5%
WW 2,829 2,615 8.2% 5.9% 2.3%
DIABETES CARE
-------------
US 603 576 4.7% 4.7% -
Intl 610 575 6.1% 3.2% 2.9%
WW 1,213 1,151 5.4% 4.0% 1.4%
ETHICON
-------
US 1,019 857 18.9% 18.9% -
Intl 1,260 1,137 10.8% 6.1% 4.7%
WW 2,279 1,994 14.3% 11.6% 2.7%
ETHICON ENDO-SURGERY
--------------------
US 990 943 5.0% 5.0% -
Intl 1,374 1,187 15.8% 10.7% 5.1%
WW 2,364 2,130 11.0% 8.2% 2.8%
ORTHO-CLINICAL
DIAGNOSTICS
--------------
US 552 561 -1.6% -1.6% -
Intl 467 400 16.8% 12.2% 4.6%
WW 1,019 961 6.0% 4.1% 1.9%
VISION CARE
-----------
US 481 465 3.4% 3.4% -
Intl 845 764 10.6% 5.4% 5.2%
WW 1,326 1,229 7.9% 4.6% 3.3%
TOTAL MEDICAL DEVICES
AND DIAGNOSTICS
---------------------
US 5,751 5,428 6.0% 6.0% -
Intl 6,606 5,994 10.2% 5.6% 4.6%
WW 12,357 11,422 8.2% 5.8% 2.4%
------ ------ --- --- ---
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Reported in U.S. sales
(4) Included in Other
(5) Includes sales of Drug-Eluting Stents for Q2 2010 of $59, $108
and $167MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and
$234MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2010 of $119,
$238 and $357MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,
$349 and $485MM Domestic, International and Worldwide respectively
(6) Conforms to current presentation
SOURCE Johnson & Johnson
Copyright (C) 2010 PR Newswire. All rights reserved